Drugs / NPMW-peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02750995 | Apr 2016 → Jan 2018 | acute myeloid leukemia, myelodysplastic syndrome | Daniel El Fassi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPMW-peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02750995 ↗ |
| Action | Deplete | “hence immune-mediated tumor cell killing” NCT02750995 ↗ |
| Modality | Vaccine | “experimental peptide vaccination” NCT02750995 ↗ |